Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhan-Ying Han

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cell Death & Disease|October 22, 2021
Role of GALNT4 in protecting against cardiac hypertrophy through ASK1 signaling pathwayBin-Bin Zhang, Lu Gao, Qin Yang, et al.
Free Radical Biology & Medicine|October 18, 2023
RNF13 protects against pathological cardiac hypertrophy through p62-NRF2 pathwaySen Guo, Bin-Bin Zhang, Lu Gao, et al.
Journal of Geriatric Cardiology : JGC|November 16, 2023
Drug-coated balloons for the treatment of ostial left anterior descending or ostial left circumflex artery lesions: a patient-level propensity score-matched analysisLiang Pan, Wen-Jie Lu, Zhan-Ying Han, et al.
American Journal of Translational Research|October 17, 2022
Stentless at ostium: a novel approach for treating ostial left anterior descending or left circumflex coronary artery lesions with drug-coated balloonsWen-Jie Lu, Liang Pan, Zhan-Ying Han, et al.
Cell Communication and Signaling : CCS|September 11, 2024
TMEM100 acts as a TAK1 receptor that prevents pathological cardiac hypertrophy progressionBin-Bin Zhang, Yi-Lin Zhao, Yan-Yu Lu, et al.
European Journal of Medical Research|March 3, 2026
Predictive value of C-reactive protein-albumin-lymphocyte index for in-stent restenosis in acute coronary syndrome patients undergoing drug-eluting stentingYan-Ge Wang, Guo-Liang Hao, Fan Yang, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cell Death & Disease|October 22, 2021
Role of GALNT4 in protecting against cardiac hypertrophy through ASK1 signaling pathwayBin-Bin Zhang, Lu Gao, Qin Yang, et al.
Free Radical Biology & Medicine|October 18, 2023
RNF13 protects against pathological cardiac hypertrophy through p62-NRF2 pathwaySen Guo, Bin-Bin Zhang, Lu Gao, et al.
Journal of Geriatric Cardiology : JGC|November 16, 2023
Drug-coated balloons for the treatment of ostial left anterior descending or ostial left circumflex artery lesions: a patient-level propensity score-matched analysisLiang Pan, Wen-Jie Lu, Zhan-Ying Han, et al.
American Journal of Translational Research|October 17, 2022
Stentless at ostium: a novel approach for treating ostial left anterior descending or left circumflex coronary artery lesions with drug-coated balloonsWen-Jie Lu, Liang Pan, Zhan-Ying Han, et al.
Cell Communication and Signaling : CCS|September 11, 2024
TMEM100 acts as a TAK1 receptor that prevents pathological cardiac hypertrophy progressionBin-Bin Zhang, Yi-Lin Zhao, Yan-Yu Lu, et al.
European Journal of Medical Research|March 3, 2026
Predictive value of C-reactive protein-albumin-lymphocyte index for in-stent restenosis in acute coronary syndrome patients undergoing drug-eluting stentingYan-Ge Wang, Guo-Liang Hao, Fan Yang, et al.
Pageof 2